Amylyx Pharmaceuticals, Inc. AMLX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $229.14M+283% | $226.65M+193% | $225.18M+213% | $58.09M-22.6% | $59.76M-65.0% | ||
| $50.63M-64.9% | $90.33M-8.9% | $118.81M-26.9% | $122.74M-47.7% | $144.3M-28.8% | ||
| $27.17M-41.2% | $33.69M-34.4% | $39.48M-26.6% | $39.36M-36.5% | $46.22M-24.2% | ||
| $285.02M+31.9% | $323.67M+70.9% | $353.38M+44.1% | $186.89M-42.8% | $216.14M-47.4% | ||
| $212K-74.0% | $310K-67.7% | $399K-68.1% | $445K-69.8% | $816K-66.8% | ||
| $4.88M+289% | $5.18M+193% | $5.48M+7.4% | $5.81M+110% | $1.26M-61.4% | ||
| —— | —— | —— | —— | $11K-97.8% | ||
| $293.6M+33.7% | $332.65M+71.8% | $362.74M+44.7% | $194.6M-41.4% | $219.68M-47.4% | ||
| $15.68M+10.5% | $16.96M-45.0% | $16.38M-67.2% | $12.53M-77.2% | $14.19M-81.0% | ||
| $11.28M-6.5% | $17.91M-25.2% | $19.47M-61.4% | $17.47M-72.2% | $12.07M-82.2% | ||
| $1.16M+9.5% | $1.26M-17.1% | $981K-50.3% | $665K-71.9% | $1.06M-54.4% | ||
| $15.97M-11.0% | $22.69M-20.1% | $25.79M-52.2% | $21.42M-69.4% | $17.93M-80.4% | ||
| $4.48M+1,269% | $4.7M+915% | $4.95M+733% | $5.3M+586% | $327K-76.3% | ||
| $20.44M+12.0% | $27.39M-5.1% | $30.75M-43.6% | $26.72M-62.3% | $18.26M-80.4% | ||
| $11K+22.2% | $11K+57.1% | $11K+57.1% | $9K+28.6% | $9K+28.6% | ||
| $1.07B+26.3% | $1.06B+36.9% | $1.05B+37.3% | $851.36M+12.3% | $844.01M+12.8% | ||
| -$792.71M-23.4% | -$751.43M-23.9% | -$718.43M-26.2% | -$684.04M-37.8% | -$642.6M-51.6% | ||
| $240K— | $404K+539% | $815K+27.1% | $551K+668% | $0+100% | ||
| $273.16M+35.6% | $305.26M+85.3% | $332M+69.2% | $167.88M-35.8% | $201.42M-37.9% | ||
| $293.6M+33.7% | $332.65M+71.8% | $362.74M+44.7% | $194.6M-41.4% | $219.68M-47.4% | ||
| $50.63M— | $90.33M— | $118.81M— | $122.74M— | —— | ||
| —— | —— | —— | —— | $11K-97.8% | ||
| $4.88M+289% | $5.18M+193% | $5.48M+7.4% | $5.81M+110% | $1.26M-61.4% | ||
| —— | —— | —— | —— | —— | ||
| $4.88M+289% | $5.18M+193% | $5.48M+7.4% | $5.81M+110% | $1.26M-61.4% | ||
| —— | —— | —— | —— | $11K-97.8% | ||
| $4.88M+289% | $5.18M+193% | $5.48M+7.4% | $5.81M+110% | $1.26M-61.4% | ||
| —— | —— | —— | —— | $11K-97.8% | ||
| $11.28M-6.5% | $17.91M-25.2% | $19.47M-61.4% | $17.47M-72.2% | $12.07M-82.2% | ||
| $11.28M-6.5% | $17.91M-25.2% | $19.47M-61.4% | $17.47M-72.2% | $12.07M-82.2% | ||
| $5.63M+307% | $5.96M+201% | $5.94M+16.4% | $5.96M+89.8% | $1.38M-62.6% | ||
| $1.07B+26.3% | $1.06B+36.9% | $1.05B+37.3% | $851.36M+12.3% | $844.01M+12.8% | ||
| $11K+22.2% | $11K+57.1% | $11K+57.1% | $9K+28.6% | $9K+28.6% | ||
| $986K-32.0% | $985K-31.9% | $983K-31.8% | $1.45M+102% | $1.45M+102% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Amylyx Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 17.85 — current assets exceed current liabilities.
- Where does Amylyx Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.